From the WashU School of Medicine News…
Clinical scientists at Washington University School of Medicine in St. Louis and University College London are collaborating with pharmaceutical companies AbbVie, Biogen, Bristol Myers Squibb and Roche to investigate the role of neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease.
NfL is a protein that provides structural support to nerve cells. It is naturally released into cerebrospinal fluid and blood and is increased in a wide range of nervous system diseases, thought to reflect active damage. However, relatively little is known about its structure and turnover in humans, limiting its potential use as a biomarker.
The NfL Consortium, led by Randall Bateman, MD, of Washington University, and Ross Paterson, MRCP, PhD, of University College London, aims to better understand the structure and role of NfL across these different diseases. The consortium aims to understand how NfL is produced and cleared by the nervous system, and whether increased levels reflect increased rates of cell damage, cell production or failed brain clearance. They will use human stem cell models as well as human samples and tissues.
“The potential for discovery of new findings of neurofilament light chain as a neurodegenerative biomarker is multiplied by academic and industry partners coming together and sharing knowledge and resources in a pre-competitive space,” Bateman said. “The NfL Consortium allows leading groups to accelerate research and speed informative clinical studies and development of treatments for neurodegenerative diseases.”
Visit the News Hub for the complete story.